[1]Aguzzi A, Sigurdson C, Heikenwaelder M. Molecular mechanisms of prion pathogenesis. Annual Review of Pathology-mechanisms of Disease, 2008, 3: 11-40.[2]Linden R, Martins V R, Prado M A, Cammarota M, Izquierdo I, Brentani R R. Physiology of the prion protein. Physiological Reviews, 2008, 88(2): 673-728.[3]Wu G. Nakajima K, Takeyama N, Yukawa M, Taniuchi Y, Sakudo A, Onodera T. Species-specific anti-apoptotic activity of cellular prion protein in a mouse PrP-deficient neuronal cell line transfected with mouse, hamster, and bovine Prnp. Neuroscience Letters, 2008, 446(1): 11-15.[4]Prusiner S B. Prions. Proceedings of the National Academy of Sciences of the USA, 1998, 95(23): 13363.[5]Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science, 2005, 308(5726): 1314-1318.[6]Soulet D, Rivest S. Bone-marrow-derived microglia: myth or reality? Current Opinion in Pharmacology, 2008, 8(4): 508-518.[7]Garden G A, Möller T. Microglia biology in health and disease. Journal of Neuroimmune Pharmacology, 2006, 1(2): 127-137.[8]Ransohoff R M, Perry V H. Microglial physiology: unique stimuli, specialized responses. Annual Review of Immunology, 2009, 27: 119-145.[9]Colton C A. Heterogeneity of microglial activation in the innate immune response in the brain. Journal of Neuroimmune Pharmacology, 2009, 4(4): 399-418.[10]Mosser D M. The many faces of macrophage activation. Journal of Leukocyte Biology, 2003, 73(2): 209-212.[11]Latz E. The inflammasomes: mechanisms of activation and function. Current Opinion in Immunology, 2010, 22(1): 28-33.[12]Martinez F O, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annual Review of Immunology, 2009, 27: 451-483.[13]Henn A, Lund S, Hedtjärn M, Schrattenholz , Pörzgen P, Leist M. The suitability of BV2 cells as alternative model system for primary microglia cultures or for animal experiments examining brain inflammation. Altex, 2009, 26(2): 83.[14]Wong M L, Medrano J F. Real-time PCR for mRNA quantitation. Biotechniques, 2005, 39(1): 75.[15]Gordon S. Alternative activation of macrophages. Nature Reviews Immunology, 2003, 3(1): 23-35.[16]Davis B K, Wen H, Ting J P Y. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annual Review of Immunology, 2011, 29: 707-735.[17]Franchi L, Eigenbrod T, Muñoz-Planillo R, Nuñez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nature Immunology, 2009, 10(3): 241-247.[18]Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annual Review of Immunology, 2009, 27: 229-265.[19]Schroder K, Tschopp J. The inflammasomes. Cell, 2010, 140(6): 821-832.[20]Hume D A, Ross I L, Himes S R, Sasmono R T, Wells C A, Ravasi T. The mononuclear phagocyte system revisited. Journal of Leukocyte Biology, 2002, 72(4): 621-627.[21]Nguyen M D, Julien J P, Rivest S. Innate immunity: the missing link in neuroprotection and neurodegeneration? Nature Reviews Neuroscience, 2002, 3(3): 216-227.[22]Adams D O, Hamilton T A. The cell biology of macrophage activation. Annual Review of Immunology, 1984, 2(1): 283-318.[23]Colton C A, Mott R T, Sharpe H, Xu Q, Van Nostrand W E, Vitek M P. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. Journal of Neuroinflammation, 2006, 3(1): 27. |